Ken Griffin Cytokinetics Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$51.22 - $60.16 $1.31 Million - $1.54 Million	25,600 Added 18.13%	166,800 $8.81 Million
Q2 2024 Aug 14, 2024	SELL	$47.86 - $75.05 $20 Million - $31.3 Million	-417,100 Reduced 74.71%	141,200 $7.65 Million
Q1 2024 May 15, 2024	SELL	$63.75 - $108.06 $18.2 Million - $30.9 Million	-285,700 Reduced 33.85%	558,300 $39.1 Million
Q4 2023 Feb 14, 2024	BUY	$26.88 - $83.49 $20.5 Million - $63.6 Million	762,200 Added 931.78%	844,000 $70.5 Million
Q3 2023 Nov 14, 2023	BUY	$29.46 - $36.61 $1.16 Million - $1.44 Million	39,300 Added 92.47%	81,800 $2.41 Million
Q2 2023 Aug 14, 2023	BUY	$32.62 - $40.75 $35,882 - $44,825	1,100 Added 2.66%	42,500 $1.39 Million
Q1 2023 May 15, 2023	SELL	$33.36 - $45.71 $977,448 - $1.34 Million	-29,300 Reduced 41.44%	41,400 $1.46 Million
Q4 2022 Feb 14, 2023	BUY	$35.77 - $51.11 $1.06 Million - $1.52 Million	29,700 Added 72.44%	70,700 $3.24 Million
Q3 2022 Nov 14, 2022	SELL	$38.54 - $54.52 $231,240 - $327,120	-6,000 Reduced 12.77%	41,000 $1.99 Million

410

125M

4.6M

2.43M

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $4.92B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.